Ann: Conclusion of Genentech Antimicrobial Collaboration, page-6

i think the spike in mid 2015 was due to cancer and myc results. See below part of ann March 30 2015

if i recall correctly the more substantial rise to 5c and subsequent settle started early 2017 following 19th December 2016 announcement that Genentech had extended the collaboration.

Its a good thing to see they already were able to raise 14 million , more than ever before, already in quick time. Must be some confidence returnibg


Phylogica Peptide Fusion Kills Aggressive Breast Cancer Cells
• Phylogica’s peptide fusions kill aggressive, drug resistant breast cancer cells
• Phylomer peptide fusions significantly boost potency of cancer drugs
• In vivo evidence of potent Phylomer fusion activity against Myc – a ‘holy
grail’ cancer target
Perth, Australia March 30 2015: A pilot study by one of Australia’s leading breast
cancer experts, Associate Professor Pilar Blancafort, a member of the Harry Perkins
Institute of Medical Research, shows that Phylogica’s cell penetrating peptides
(CPPs) linked with the Omomyc drug kill aggressive drug resistant breast cancer
cells in vivo